Nanobiotix (NASDAQ:NBTX) Sees Strong Trading Volume – Time to Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw unusually-strong trading volume on Friday . Approximately 62,552 shares were traded during mid-day trading, an increase of 81% from the previous session’s volume of 34,487 shares.The stock last traded at $19.61 and had previously closed at $19.67.

Analyst Ratings Changes

NBTX has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Nanobiotix to a “hold” rating in a report on Saturday, October 25th. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a research report on Tuesday. Finally, Leerink Partners set a $14.00 price target on Nanobiotix in a research note on Thursday, September 18th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $11.00.

Nanobiotix Stock Up 1.0%

The firm’s fifty day simple moving average is $17.44 and its 200-day simple moving average is $9.59.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.